Stanley Erck

Former CEO, Novavax

Search every verified Stanley Erck interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Stanley Erck, who served as CEO of Novavax until his retirement in early 2023, oversaw the company's transition from a clinical-stage biotech to a commercial vaccine manufacturer during the COVID-19 pandemic. In a January 2023 interview, Erck stated that the company had grown from fewer than 100 employees and less than $100 million in funding to over 2,000 employees and more than $1 billion in cash, and had generated $2 billion in revenue in 2022. He described the company's COVID-19 vaccine as "best-in-class" in terms of efficacy, safety, and stability, and noted that it had been approved in 47 countries. Erck also said the U.S. was "the last country" to approve the vaccine, and that the company was working with the FDA to expand its label for all age groups and booster use. Throughout 2021 and 2022, Erck frequently discussed the company's manufacturing scale-up and global distribution strategy. He stated that Novavax had built manufacturing capacity in eight countries, including partnerships with the Serum Institute of India, and aimed to produce "a couple billion doses" per year. Erck emphasized the vaccine's advantages, including storage at refrigerated temperatures and a nine-month shelf life. He also noted that the company was developing a combined flu-COVID vaccine and an Omicron-specific variant vaccine. On the company's financial outlook, Erck projected full-year 2022 revenue of $4 to $5 billion, though the company later slashed that guidance by about 50% due to lower-than-expected demand, particularly from the COVAX facility.